North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane

INTRODUCTION: Angiogenesis is an established target for the treatment of MBC. Aflibercept (VEGF-Trap) is a humanized fusion protein, which binds VEGF-A, VEGF-B, and PIGF-1 and -2. PATIENTS AND METHODS: A 2-stage phase II study with primary end points of confirmed tumor response and 6-month progressi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Sideras, Kostandinos, Dueck, Amylou C., Hobday, Timothy J., Rowland, Kendrith M., Allred, Jacob B., Northfelt, Donald W., Lingle, Wilma L., Behrens, Robert J., Fitch, Tom R., Nikcevich, Daniel A., Perez, Edith A.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3586936/
https://ncbi.nlm.nih.gov/pubmed/23083501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2012.09.007
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki